Peter Weisenseel

Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (‘clinical super response’): Week 28 results from the ongoing phase <scp>IIIb</scp> randomized, double‐blind, parallel‐group, <scp>GUIDE</scp> study

Knut Schäkel, Kristian Reich, K. Asadullah et al. · Journal of the European Academy of Dermatology and Venereology · 2023 · 100 citations · Full text

Pharmacy, Dermatology, Pharmacotherapy +17

IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)

Kilian Eyerich, Peter Weisenseel, Andreas Pinter et al. · BMJ Open · 2021 · 80 citations · Full text

Medicine, Dermatology, Pharmacotherapy +17

“Borrelia-associated early-onset morphea”: A particular type of scleroderma in childhood and adolescence with high titer antinuclear antibodies?

Joerg C. Prinz, Zsuzsanna Kutasi, Peter Weisenseel et al. · Journal of the American Academy of Dermatology · 2008 · 53 citations

Medicine, Immunology, Pediatrics +9

Deep Subcutaneous Application of Poly-&lt;i&gt;L&lt;/i&gt;-Lactic Acid as a Filler for Facial Lipoatrophy in HIV-Infected Patients

Claudia Borelli, Christian Kunte, Peter Weisenseel et al. · Skin Pharmacology and Physiology · 2005 · 42 citations · Full text

Pharmacy, Pharmaceutics, Pharmacotherapy +14

Detection of the 47-kilodalton membrane immunogen gene of Treponema pallidum in various tissue sources of patients with syphilis

Alexander V. Kouznetsov, Peter Weisenseel, Paul Trommler et al. · Diagnostic Microbiology and Infectious Disease · 2005 · 36 citations

Veterinary Medicine, Immunology, Infectious Diseases +8